HOME >> BIOLOGY >> NEWS
Experimental therapy stops allergic reactions in mice

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) have devised a new, experimental approach to treating allergic diseases. In mice, the scientists used a genetically engineered molecule to connect two receptors on the key immune system cells that cause allergic reactions. Cross-linking these receptor molecules short-circuited the type of allergic reaction that leads to asthma, allergic rhinitis, and even the potentially deadly anaphylaxis caused by food allergy.

This work represents an entirely new approach to treating allergic diseases, says NIAID Director Anthony S. Fauci, M.D. The prevalence of allergic disease has increased significantly in recent decades, and there simply are not many promising therapeutic strategies out there. We hope that NIAIDs continued support of research into the mechanisms of allergy will lead to other innovative concepts like this one.

This research does what science is supposed to do, says Marshall Plaut, M.D., chief of NIAIDs Allergic Mechanisms Section. The researchers succeeded in translating a scientific observation into a clever therapeutic idea. Details of this work, performed by a team of scientists at the University of California at Los Angeles (UCLA) and the University of New Mexico, appear in the May issue of Nature Medicine.

The scientists designed and created a molecule called GE2 that acts on two types of immune system cells central to allergic reactions: mast cells and basophils. In people with allergies, these cells respond to ordinarily harmless substances, such as pollen or peanut proteins, by releasing chemicals such as histamine that trigger the symptoms of allergic reactions. Histamine, for example, causes swelling, sneezing, itching, and irritation.

GE2 binds to receptor molecules on mast cells and basophils that control the release of histamine. One of these receptor molecules is like a gas pedal: it makes the allergic reaction go.
'"/>

Contact: Jeff Minerd
jminerd@niaid.nih.org
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
30-Apr-2002


Page: 1 2

Related biology news :

1. Experimental drug shown to block mutant protein causing blood disease
2. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
3. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
4. Experimental Biology 2004 - Translating the Genome
5. Experimental Biology 2004 meets in Washington, D.C. April 17-21
6. Experimental hantavirus vaccine elicits strong antibody response in primates
7. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental Biology 2003 meets in San Diego April 11-15
10. Experimental gene switch increases lifespan with no ill effects
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2018)... ... 20, 2018 , ... When designing a fluidic system for ... ensure what is designed can be manufactured reliably and cost effectively while meeting ... path design with specific focus on layered manifold technology. , Layered manifold technology ...
(Date:8/17/2018)... N.J. and LIEGE, Belgium (PRWEB) , ... ... ... Diagenode today announced the acquisition of NXT-Dx, an established epigenetics service provider ... services including a number of targeted DNA methylation assays using pyrosequencing or ...
(Date:8/17/2018)... , ... August 16, 2018 , ... ... world’s first private cord blood bank to separate and store stem cells in ... Center, and Brian Sheehy, M.D. M.A. C.F.A., Founder and Managing Partner IsZo Capital, ...
Breaking Biology News(10 mins):
(Date:9/1/2018)... ... August 31, 2018 , ... Rudina Thanasi, ... of a proprietary biofield energy treated nutraceutical supplement used in combating inflammation and ... response and blood, as well as, organ-specific inflammation. The reported data is as ...
(Date:8/29/2018)... ... August 28, 2018 , ... Nanovis , an ... successful completion of a $5.5 million funding round managed by Commenda Securities. Key ... Capital, and Ellipsis Ventures. , “Our investment in Nanovis is consistent with our ...
(Date:8/29/2018)... ... August 28, 2018 , ... CEO and founder ... safety study performed on an allogeneic (donor derived) stem cell product for osteoarthritis ... conference in September. He is also the organizer of Breakout Session 4: ...
(Date:8/26/2018)... ... August 23, 2018 , ... ... engineers, and scientists from around the world, will host the 4th Annual Microbiology ... array of industries and disciplines, encompassing various research areas including medicine, agriculture, and ...
Breaking Biology Technology:
Cached News: